There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...

In today's digital age, where most of the time is spent on mobile and laptop screens, lack of sleep and stress have a bad ...

It seemed like a simple idea. Design a device that will make it possible for a human eye to remain alive and functional ...

Latanoprostene bunod 0.024% significantly reduced IOP across patient groups and appeared well regarded among physicians and ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

The UC Davis Department of Ophthalmology has received a five-year, $3.6 million grant from the National Eye Institute to ...

The Vision Center at Children’s Hospital Los Angeles is developing a protocol for a phase 1 clinical trial for the first gene ...